Cervical Cancer Clinical Trials (as of October 2017)

ENGOT-cx9/GEICO/REGN

Leading group: GEICO

Clinical Trial Study: An open-label, randomized, GOG/ENGOT phase 3 trial of anti-PD1 cemiplimab versus investigator's choice chemotherapy in >2 line recurrent cervical cancer

Number of patients accrued: 0

Planned number of patients: 436

Participating groups: 

BGOG, CEEGOG, MITO, PGOG

Planned start in 1Q 2018

 

 

ENGOT-cx8/BGOG-cx8/GCT1015-05

Leading group: BGOG

Clinical Trial Study: A phase 2 open-label trial of Tisotumab Vedotin (HuMax® - TF-ADC) alone or in combination in first line recurrent or stage IVB cervical cancer

Number of patients accrued: 0

Planned number of patients: 90

Participating groups: TBA

Planned start in 2Q 2018

 

  

ENGOT-cx7/NSGO/cc1-MaRuC

Leading group: NSGO

Clinical Trial Study: A randomized double-blind placebo-controlled phase II trial of Rucaparib maintenance therapy for patienst with locally advanced cancer - MaRuC

Number of patients accrued: 0

Planned number of patients: 162

Participating groups: 

BGOG, Cancer Trials Ireland, CEEGOG, EORCT, GEICO, ISGO, MITO, NCRI, NOGGO, PGOG

Planned start in 2Q 2018

 

 

ENGOT-cx6/BGOG-cx6/GCT1015-04

Leading group: BGOG

Clinical Trial Study: A single arm, multicenter, international trial of Tisotumab Vedotin (HuMax® - TF-ADC) in previously treated, recurrent or metastatic cervical cancer 

Number of patients accrued: 0

Planned number of patients: 100

Participating groups:

AGO, CEEGOG, GEICO, MITO, NSGO

Planned start in 2Q 2018

 

 

ENGOT-cx5/A-AGO/ADVANCE

Leading group: A-AGO

Clinical Trial Study: ADVANCE (ADVAxis Immunotherapy with Nivolumab to treat recurrent or metastatic CErvical Cancer), A randomized phase II study to evaluate the safety and efficacy of ADXS-602 in combination with Nivolumab

Number of patients accrued: 0

Planned number of patients: 460

Participating groups: TBA

Planned start in 2018

 

 

ENGOT-cx4/GINECO/SENTICOL

Leading group: GINECO

Clinical Trial Study: International prospective validation trial of sentinel node biopsy in cervical cancer

Number of patients accrued: 0

Planned number of patients: 950

Participating groups: 

AGO, Cancer Trials Ireland, MaNGO, NCRI, NSGO

Planned start in 2018

 

 

ENGOT-cx3/CEEGOG/ABRAX

Leading group: CEEGOG

Clinical Trial Study: Abandoning of radical hysterectomy in cervical cancer - retrospective trial

Number of patients accrued: 0

Planned number of patients: TBA

Participating groups: 

AGO, BGOG, MITO

Planned start in 2018

 

 

ENGOT-cx2/CEEGOG/SENTIX

Leading group: CEEGOG

Clinical Trial Study: SENTIX (SENTinel lymph node in cervIX cancer) - a prospective observational trial on sentinel lymph node biopsy in patients with early stage cervical cancer

Number of patients accrued: 159

Planned number of patients: 350

Participating groups:

BGOG, other TBA

 

 

ENGOT-cx1/BGOG-cx1

Leading group: BGOG

Clinical Trial Study: A randomized phase II trial of paclitaxel-carboplatin 3-weekly with or without Nintedanib (BIBFI 120) in advanced or recurrent cervical carcinoma

Number of patients accrued: 96

Planned number of patients: 120

Participating groups:

AGO, GEICO, MaNGO, MITO, NOGGO